Mercer Global Advisors
HRMY icon

Mercer Global Advisors’s Harmony Biosciences HRMY Stock Holding History

Mercer Global Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$414K Buy
14,779
+754
+5% +$24.7K ﹤0.01% 2131
2025
Q4 		$525K Buy
+14,025
New +$461K ﹤0.01% 1822
2023
Q1 		– Sell
-4,011
Closed -$221K – 1992
2022
Q4 		$221K Buy
+4,011
New +$221K ﹤0.01% 1656

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Mercer Global Advisors's HRMY Position: Q1 2026 in Review

Mercer Global Advisors increased its Harmony Biosciences (HRMY) stake by 5.4% in Q1 2026, buying an estimated $24.7K and bringing the position to 14,779 shares worth $414K. The position accounts for ﹤0.01% of the portfolio, ranked #2131.

Mercer Global Advisors first reported a position in HRMY in Q4 2022 and has held it in 3 quarters since. The position peaked at $525K in Q4 2025. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Mercer Global Advisors held 14,779 shares of Harmony Biosciences worth $414K as of Q1 2026.
  • Mercer Global Advisors bought 754 Harmony Biosciences shares in Q1 2026, an estimated $24.7K.
  • Harmony Biosciences made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #2131 holding.
  • Mercer Global Advisors first reported a position in Harmony Biosciences in Q4 2022 and has held it in 3 quarters since.
  • Mercer Global Advisors's Harmony Biosciences position peaked at $525K in Q4 2025.
  • 309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.